Stoke Therapeutics (Stoke Therapeutics) Other Stockholders Equity : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Stoke Therapeutics Other Stockholders Equity?

Stoke Therapeutics's Other Stockholders Equity for the quarter that ended in Mar. 2024 was $0.00 Mil.

Stoke Therapeutics's quarterly Other Stockholders Equity increased from Sep. 2023 ($-0.00 Mil) to Dec. 2023 ($0.00 Mil) and increased from Dec. 2023 ($0.00 Mil) to Mar. 2024 ($0.00 Mil).

Stoke Therapeutics's annual Other Stockholders Equity declined from Dec. 2021 ($-0.00 Mil) to Dec. 2022 ($-0.00 Mil) but then increased from Dec. 2022 ($-0.00 Mil) to Dec. 2023 ($0.00 Mil).

Stoke Therapeutics Other Stockholders Equity Historical Data

The historical data trend for Stoke Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stoke Therapeutics Other Stockholders Equity Chart

Stoke Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Stockholders Equity

Get a 7-Day Free Trial

Stoke Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Stockholders Equity	Get a 7-Day Free Trial															-	-	-	-	-

Stoke Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

Stoke Therapeutics Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Stoke Therapeutics's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Stoke Therapeutics (Stoke Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stoke Therapeutics Inc (NAS:STOK) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

0GT:Germany

Address

45 Wiggins Avenue, Bedford, MA, USA, 01730

Website

https://www.stoketherapeutics.com

Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The company primarily operates in the U.S.

Executives

Barry Ticho	officer: Chief Medical Officer	C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Ian F Smith	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Jonathan Allan	officer: General Counsel & Corp Sec	C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730
Huw M. Nash	officer: COO & CBO	C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Atp Life Science Ventures, L.p.	10 percent owner	230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169
Atp Iii Gp, Ltd.	10 percent owner	230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169
Skorpios Trust	10 percent owner	195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Montrago Trustees Ltd	10 percent owner	195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Blue Horizon Enterprise Ltd	10 percent owner	3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Ezbon International Ltd	10 percent owner	3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Gene Liau	officer: EVP Research & Preclinical Dev	C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Arthur A Levin	director	1896 RUTHERFORD ROAD, CARLSBAD CA 92008
Stephen J Tulipano	officer: CFO	C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Arthur Tzianabos	director	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Kaye Edward M. Md	director, officer: CEO	3450 MONTE VILLA PARKWAY, BOTHELL WA 98011